MT-RNR1 and type 2 diabetes mellitus: In support, some studies have reported reduced plasma levels of MOTS-c in people with obesity, type 2 diabetes [32, 37] or impaired coronary endothelial function [38], and exogenous MOTS-c treatment restores skeletal muscle insulin sensitivity in mice [14, 27].